Increased AhR activity is associated with autoimmune disease pathology and preclinical disease models, with AhR agonists suppressing inflammation in models of inflammatory bowel disease, SLE, and rheumatoid arthritis [70], [71]. Here, AHR is linked to systemic lupus erythematosus.